Clinical Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Peripheral T-Cell Lymphoma.
10.7534/j.issn.1009-2137.2019.06.043
- Author:
Song XUE
1
;
Fu-Hong ZHANGLIU
1
;
Yong-Ping ZHANG
1
;
Ting-Ting LI
1
;
Yuan-Yuan LIU
1
;
Jing-Bo WANG
2
Author Information
1. Department of Hematology, Aerospace Center Hospital，Beijing 100049, China.
2. Department of Hematology, Aerospace Center Hospital，Beijing 100049, China,E-mail：wangjingbo@asch.net.cn.
- Publication Type:Journal Article
- MeSH:
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, T-Cell, Peripheral;
therapy;
Retrospective Studies;
Transplantation Conditioning;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2019;27(6):1973-1978
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed or refractory peripheral T-cell lymphoma(PTCL).
METHODS:The clinical data of 6 patients with relapsed or refractory PTCL undergoing allo-HSCT from Sep. 2014 to Sep. 2018 in the department of hematology, aerospace center hospital were retrospectively analyzed. Complications and disease-free survival after HSCT were observed.
RESULTS:All the patients could well tolerate the conditioning regimen and acquired hematopoietic recon-struction. Following up till December 2018, with a median time of 11.5 months (1-51); acute GVHD developed in 2 cases and chronic GVHD developed in 5 cases, Among 6 cases one case died of viral pheumonia and the other 5 patients remained disease-free survival. The longest disease-free survival time has reached 51 months.
CONCLUSION:allo-HSCT is a safe and effective method for relapsed or refractory peripheral T-cell lymphoma, which can be chosen as salvage treatment method for patients with primary resistance. Optimization of the conditioning regimen may result in better efficacy of allo-HSCT.
